Ionis Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2026 was $3,450 Mil.
During the past 12 months, Ionis Pharmaceuticals's average Total Assets Growth Rate was 129.20% per year.
During the past 3 years, the average Total Assets Growth Rate was 15.70% per year.
During the past 5 years, the average Total Assets Growth Rate was 11.80% per year.
During the past 10 years, the average Total Assets Growth Rate was 14.50% per year.
During the past 13 years, Ionis Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 162.30%. The lowest was -21.60%. And the median was 10.80%.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Ionis Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Ionis Pharmaceuticals Total Assets Related Terms
Ionis Pharmaceuticals Total Assets Historical Data
* Premium members only.
The historical data trend for Ionis Pharmaceuticals's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Ionis Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ionis Pharmaceuticals (LTS:0JDI) has a Total Assets of $3,450 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Ionis Pharmaceuticals and its competitors.
Is Ionis Pharmaceuticals' Total Assets too high?
Ionis Pharmaceuticals' current Total Assets is $3,450 Mil. Overall, Ionis Pharmaceuticals has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' Total Assets compare to EXEL and BBIO?
Ionis Pharmaceuticals' Total Assets of $3,450 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Ionis Pharmaceuticals and its competitors. Ionis Pharmaceuticals's current Total Assets is $3,450 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ionis Pharmaceuticals (LTS:0JDI) is currently considered Significantly Overvalued. The stock's GF Value™ is $52.88, compared to a current price of $80.25 — trading 51.8% above its estimated fair value. The current Total Assets is $3,450 Mil. Ionis Pharmaceuticals' overall GF Score™ is 66/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Ionis Pharmaceuticals (LTS:0JDI), the current Total Assets is $3,450 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ionis Pharmaceuticals (LTS:0JDI) Overvalued in 2026?
Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued.
The current stock price of $80.25 is trading 51.8% above its estimated GF Value™ of $52.88.
GuruFocus considers Ionis Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for LTS:0JDI:
Total Assets: $3,450 Mil
GF Value™: $52.88 vs. price of $80.25 (51.8% above fair value)
No single metric tells the full story. See the LTS:0JDI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
66GF Score
Get the complete analysis for LTS:0JDI
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0JDI has been successfully added to your 
